Stock NORD NORDA ASA
Add to a list
To use this feature you must be a member
Log inSign up

Financials Norda ASA

Equities

NORD

NO0010285190

Biotechnology & Medical Research

End-of-day quote Norwegian OTC
Other stock markets
 03:30:00 10/05/2024 am IST 		5-day change 1st Jan Change
41 NOK 0.00% Intraday chart for Norda ASA 0.00% 0.00%
2023 Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2022 CI
2022 Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2021 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 89.83 85.91 100.8 188.9 188.9 203.8
Enterprise Value (EV) 1 -50.2 59.27 32.06 74.94 30.16 -52.97
P/E ratio 3.78 x -0.85 x 2.49 x - - -
Yield - - - 15.8% - -
Capitalization / Revenue 1.44 x 5.1 x 1.2 x 0.4 x 1.36 x 1.59 x
EV / Revenue -0.8 x 3.52 x 0.38 x 0.16 x 0.22 x -0.41 x
EV / EBITDA - - - - - -
EV / FCF -1.4 x -38.2 x 0.62 x 0.23 x 0.6 x -0.72 x
FCF Yield -71.5% -2.62% 160% 426% 166% -138%
Price to Book 0.5 x 1.3 x 0.92 x - - -
Nbr of stocks (in thousands) 4,990 4,773 5,040 4,971 4,971 4,971
Reference price 2 18.00 18.00 20.00 38.00 38.00 41.00
Announcement Date 14/06/18 21/06/19 25/06/20 21/06/21 16/06/22 01/11/23
1NOK in Million2NOK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 62.38 16.83 83.94 469.1 139.3 128
EBITDA - - - - - -
EBIT 1 60.73 14.82 82 467 135.7 125.7
Operating Margin 97.35% 88.04% 97.69% 99.56% 97.37% 98.21%
Earnings before Tax (EBT) 1 22.74 -107.3 39.93 427.7 82.14 100.2
Net income 1 22.74 -107.3 39.93 427.7 82.14 100.2
Net margin 36.45% -637.3% 47.57% 91.17% 58.96% 78.33%
EPS 2 4.764 -21.29 8.033 - - -
Free Cash Flow 1 35.87 -1.553 51.34 319 49.96 73.3
FCF margin 57.5% -9.23% 61.16% 68% 35.86% 57.28%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) 157.76% - 128.57% 74.59% 60.83% 73.12%
Dividend per Share - - - 6.000 - -
Announcement Date 14/06/18 21/06/19 25/06/20 21/06/21 16/06/22 01/11/23
1NOK in Million2NOK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 140 26.6 68.7 114 159 257
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 35.9 -1.55 51.3 319 50 73.3
ROE (net income / shareholders' equity) 14% -88.7% 45% 334% 43.5% 35.8%
ROA (Net income/ Total Assets) 10% 1.89% 10.9% 53.9% 12.5% 11.1%
Assets 1 227.2 -5,684 367.2 792.8 657.5 906
Book Value Per Share 2 36.10 13.80 21.70 - - -
Cash Flow per Share 2 0.8300 2.700 0.6200 - - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 14/06/18 21/06/19 25/06/20 21/06/21 16/06/22 01/11/23
1NOK in Million2NOK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Diagnostics & Testing

1st Jan change Capi.
NORDA ASA Stock Norda ASA
0.00% 19.04M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-31.18% 9.59B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-6.65% 3.21B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+26.46% 2.92B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-13.96% 2.15B
VERACYTE, INC. Stock Veracyte, Inc.
-15.96% 1.79B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+72.98% 1.47B
CAREDX, INC Stock CareDx, Inc
+24.25% 770M
SEEGENE, INC. Stock Seegene, Inc.
-2.62% 761M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-25.92% 548M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. NORD Stock
  4. Financials Norda ASA
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW